NCT01183754已完成不适用
Use of a Point-of-Care Platelet Function Assay to Improve the Prediction of Atherothrombotic Events After Implantation of Drug-Eluting Stents: ASAN-VerifyNow Registry
CardioVascular Research Foundation, Korea1 个研究点 分布在 1 个国家目标入组 3,000 人开始时间: 2006年3月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 3,000
- 试验地点
- 1
- 主要终点
- Composite of all-cause death, myocardial infarction, stent thrombosis, and stroke
研究概览
简要总结
- To evaluate the role of VerifyNow test as prognostic marker in routine clinical practice using drug-eluting stents.
- To determine the add-on-effect of VerifyNow test beyond on conventional risk factors (clinical, lesions, or procedural factors).
- To compare the prognostic utility of VerifyNow test with several biomarkers.
详细描述
Predictive role of a point-of-care assay (VerifyNow test) has not been well evaluated in large number of patients receiving drug-eluting stents as a routine practice.
In addition, additional predictive effect of a point-of-care assay, as compared to conventional clinical factors or other biomarkers, might be clinically interesting and important.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Consecutive patients with established coronary artery disease receiving PCI with stent implantation
排除标准
- •Cardiogenic shock
- •Patients using concomitant medication known to affect platelet function other than aspirin (i.e. nonsteroidal antiinflammatory agents, dipyramidole, upstream glycoprotein IIb/IIIa inhibitors)
- •patients with a known platelet function disorder or a whole blood platelet count of less than 150000/μL.
结局指标
主要结局
Composite of all-cause death, myocardial infarction, stent thrombosis, and stroke
时间窗: at median 2 year after enrollment
次要结局
- target-vessel revascularization(at median 2 year after enrollment)
- Composite of cardiovascular death, MI, stent thrombosis, or stroke(at median 2 year after enrollment)
- stent thrombosis(at median 2 year after enrollment)
- death (all-cause and cardiovascular)(at median 2 year after enrollment)
- myocardial infarction(at median 2 year after enrollment)
- stroke(at median 2 year after enrollment)
- Thrombolysis In Myocardial Infarction (TIMI) major/minor bleeding(at median 2 year after enrollment)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Evaluation and Comparison of Several Point-of-care Platelet Function Tests in Predicting Clinical Outcomes in Clopidogrel Pre-treated Patients Undergoing Elective PCI.Stable Angina PectorisNCT00352014R&D Cardiologie1,000
已完成
4 期
Tailored Antiplatelet Therapy During Percutaneous Coronary Intervention in Patients With Diabetes MellitusDiabetes MellitusNCT01475552Seoul National University Bundang Hospital130
已完成
不适用
A study assessing the usefulness of measuring platelet function after cardiac surgeryCoronary Artery Disease / Coronary Artery Bypass Graft / Antiplatelet medicationsCirculatory SystemAtherosclerotic heart diseaseISRCTN43298975Wolverhampton Coronary Aftercare Support Group (UK)84
已完成
早期 1 期
The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission AggregometryNCT04822363Beth Israel Deaconess Medical Center112
已完成
4 期
Application of Platelet Function Test in Prevention of Ischemic Events After Stent Placement in Intracranial AneurysmsUnruptured Intracranial AneurysmStentsAntiplatelet DrugsNCT03989557Beijing Neurosurgical Institute314